Wednesday, June 9, 2021

ViaCyte Scores $45M For Stem Cell Therapy

San Diego-based ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sander

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---